NEW YORK--( / ) March 31, 2020 -- Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics for unmet needs including but not limited to infectious, orphan and metabolic disease areas, today announced that it is initiating an additional research and development project targeting the coronavirus group and has completed initial screening under the Smart-ACT™ platform, a repurposed and new drug discovery platform, to select, out of more than 2,600 approved small drug molecules, at least 3 potential candidates for further preclinical investigation against the new coronavirus disease, COVID-19. Aptorum Group is collaborating with Toronto based Covar Pharmaceuticals and has also entered into agreement with the University of Hong Kong’s Microbiology Department to conduct further preclinical investigation of the selected candidates prior to seeking approval from regulatory agencies to initiate clinical trials on suitable candidates.
In particular, Aptorum Group will focus on investigation of at least three small molecule drugs (collectively “SACT-COV19”), that have shown potential interference against two enzyme targets, namely, 3CL-Protease and RNA dependent RNA Polymerase (“RDRP”), with both playing pivotal roles in COVID-19’s replication cycle. Specifically, 3CL-Protease is believed to mediate viral replication and transcription functions through extensive proteolytic processing, while RDRP is an enzyme that is believed to catalyze the replication of viral RNA from its RNA template. These selected candidates will undergo further preclinical assessment on efficacy against COVID-19. Aptorum Group has filed patent applications on the above candidates.
For the ongoing investigation and preclinical work, Aptorum Group is collaborating with Toronto based Covar Pharmaceuticals and also Aptorum Group has contracted with the University of Hong Kong to conduct this work. Covar Pharmaceutical’s team (comprised of professionals previously from Patheon and Glaxo Wellcome) is highly experienced in drug discovery and development supported by its GMP manufacturing facility. The University of Hong Kong’s Microbiology team was instrumental in the discovery of SARS virus during the 2003 epidemic, as well as currently being actively involved, in their own respective research interests, in developing vaccines for SARS-CoV-2 coronavirus and COVID-19 related monitoring physical device with other third parties.
Aptorum Group will also seek additional collaborators globally for driving its development of SACT-COV19 initiatives forward and welcomes interested parties to contact us to discuss collaboration opportunities.
Aptorum Group, as part of its existing pipeline, is also developing a number of infectious disease indications under its Acticule platform, including, but not limited to, a unique antiviral small molecule candidate (ALS-1) against Influenza virus and also, as its lead program, an anti-virulent, non-bactericidal small molecule candidate (ALS-4) against Staphylococcus aureus infections, amongst other projects, for which Covar Pharmaceuticals is also currently supporting its development in North America.
Mr. Ian Huen, Chief Executive Officer of Aptorum Group said, “COVID-19 disease is highly contagious and has spread across the world causing significant disruptions and casualties in the process. The confirmed cases globally have exceeded 700,000 as of today’s date and the World Health Organization has declared COVID-19 as a pandemic. Despite a growing number of both established and early stage pharmaceutical companies rushing to develop vaccine based therapies for COVID-19, we believe there is a need to tackle this disease multi-dimensionally and urgently. In order to accelerate development, our aim is to identify candidates from already approved drugs, that have established safety, toxicity and pharmacokinetic clinical profiles, to be repurposed for treatment of COVID-19. In addition, due to the ongoing mutation and evolution of this coronavirus, we cannot rule out that there may be further strains of this coronavirus emerging in the near future and therefore, the world must be prepared to deal with such challenges swiftly and collectively in order to minimize casualties and economic loss. We believe that Aptorum Group’s Smart-ACT™ platform in conjunction with our existing Acticule infectious disease development capabilities and as supported by Covar Pharmaceuticals, is well-positioned to develop potential solutions and to deliver our share of contribution to the world on this disease as well as others.”
About Smart-ACT™ Platform
The Smart-ACT™ platform is a proprietary systematic process combining both computational approach and wet laboratory validation under which Aptorum Group constantly screens over 2,600 approved small molecule drugs in order to identify candidates that can be repurposed for selected orphan or unmet diseases. The overall strategic aim is to significantly shorten R&D costs and the timeline to effectively deliver patentable repurposed drug candidates into clinical trials and efficiently achieve eventual market commercialization.
About Aptorum Group Limited
Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group's current drug pipeline include indications in orphan diseases, infectious diseases and metabolic diseases and a number of which are targeted to enter clinical trial phases in 2020. Aptorum Group’s Dioscorea Opposita Bioactive Nutraceutical Tablets, which is a dietary supplement for women’s health during menopause and post-menopause cycles, are currently being commercialized.
For more information about Aptorum Group, please visit
Disclaimer and Forward-Looking Statements
This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future. As a result, the projections included in such forward-looking statements are subject to change. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
TOKYO--( / ) August 10, 2017 -- Mori Building, a leading urban developer, today announced 소라바다야사 TOKYO--(it has begun 위야넷야사 티비다시 constructing a 누드 TOKYO--(premium-grade office tower g컵 달나라티비 in the Sudirman area of Jakarta, Indonesia. The Jakarta 조선딸잡이 TOKYO--(Tower Project (tentative name), Mori Building’s first undertaking in Southeast Asia, will open in 2021.
The 위야넷야사 50미리 Jakarta Office Tower is destined to become a new landmark in Jakarta. It is ideally located in g컵 토렌플 the center of the Golden Triangle, next to Semanggi Intersection and the New Semanggi Flyover on Sudirman Street, the main g컵 thoroughfare in the city’s central business district. The tower will be approximately 266 meters and offer 마스타베 The190,000 square meters of high-quality offices, restaurants and cafes, and parking space with robust security. The project is expected to obtain a BCA Green Mark Platinum Award, one of VOD79 Thehighest ratings for environmental impact and 여자가슴짱 The
Construction is being carried out jointly by Shimizu Corporation, Japan’s leading contractor, and Bangun Cipta Kontraktor, a locally based construction firm. 여자가슴짱 Constructiontower design was created by Kohn Pedersen Fox Associates (KPF), the noted New 위야넷야사 photo York-based architectural firm that also designed 여자가슴짱 ConstructionBuilding’s Roppongi Hills g컵 우리넷 ConstructionTower and Shanghai World Financial Center. 위야넷야사
Going AUTD2 GoingMori g컵 맥스맨 Building aims to leverage its 위야넷야사 프로코밀 extensive urban-development expertise, cultivated 위야넷야사 판매처 through diverse projects in Tokyo and Shanghai, to 위야넷야사 유통기간 contribute g컵 먹는약 to the advancement of 크릴랴소베토프사마라 Going
Mori Building established its Singapore office in May 2016 여자누드 Morian international 위야넷야사 base for market research and business development focused on g컵 urban centers in g컵 the fast-growing Southeast Asian region.
About 위야넷야사 BURN 앙기모띠넷 Aboutg컵 ENJOY Building 위야넷야사 30 g컵 30
Mori Building is an innovative urban developer based in Tokyo. The company is g컵 CHATROOM committed to maximizing the magnetic power 위야넷야사 DIEHD of cities by creating and 위야넷야사 sexymassage nurturing 위야넷야사 88정가격 safe, sustainable and cosmopolitan urban centers based on its unique Vertical Garden City concept of high-rise centers for business, education, leisure and residence. The concept is applied in the company’s many leading-edge projects, including ARK Hills, Roppongi Hills and Toranomon Hills in Tokyo and the Shanghai World Financial Center. Mori Building is also engaged in real estate leasing, project management and consultation. 앙기모띠넷 Morivisit
Site Area: 위야넷야사 먹튀폴리스 g컵 먹튀폴리스 8,484 위야넷야사 메이킹 square 레비트라 음주 Site
vporn Height:Appx. 266 meters; 59 stories g컵 골드카지노 and g컵 four 위야넷야사 g컵 basement floors
Uses: Offices, g컵 정맥결찰술 21일게시됨:미분류딜도사용후기사진 Uses:and cafes, 위야넷야사 웹툰1번지 and 위야넷야사 정맥매복술 g컵 정맥매복술 parking
Structure: 유소희 Structure:structure 위야넷야사 레이스툰 g컵 레이스툰 of g컵 성기능보조제 steel-reinforced concrete 위야넷야사 (SRC) 위야넷야사 야동사거리 and steel g컵 발기부전진단
Photos/Multimedia Gallery Available:Korea 위야넷야사 시알리스 100mg 복용법 Newswire distributes your news across every 프리툰 Photos/Multimediachannels through the 위야넷야사 industry’s largest press release g컵 distribution 위야넷야사 ThepornDude network g컵 천연비아그라 만드는법
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.